Focus on Technology, Application, End User, Region and Competitive Landscape - Analysis and Forecast, 2020-2025
Market Report Coverage - MRD Testing Forecast Period: 2020-2025 Market Size in 2019: $694.0 Million
What are the major market drivers, challenges, and opportunities and their respective impacts in the global MRD testing market?
The global market for MRD testing is predicted to grow at a CAGR of 15.64% over the forecast period of 2020-2025.
1.1 Inclusion and Exclusion
1.2 Scope of Work
1.3 Key Questions Answered in the Report
2.1 Primary Data Sources
2.2 Secondary Data Sources
2.3 Market Estimation Model
2.4 Criteria for Company Profiling
3.1 MRD Testing
3.2 MRD Testing: Solid Tumor vs Hematological Malignancies
3.3 Market Footprint
3.4 Market Size and Future Growth Potential
4.1 Impact Analysis
4.2 Market Drivers
4.2.1 Rising Incidence of Hematologic Malignancies
4.2.2 Increasing Consumer Awareness for Tailored Therapy
4.2.3 Increase in Research Funding from National Cancer Institute
4.2.4 Increasing Disposable Income in Emerging Economies
4.3 Market Restraints
4.3.1 False Negatives and Positives
4.3.2 Uncertain Reimbursement and Regulatory Policies
4.3.3 Lack of Trained Professionals
4.3.4 Lack of Established Treatment Protocols for High-Value Tests in Emerging Economies
4.4 Market Opportunities
4.4.1 Potential Long-Term Cost Savings
4.4.2 Increasing Market Access in Emerging Economies
4.4.3 Technological Evolution of Testing
4.4.3.1 8- and 10-Color Flow Cytometry
4.4.3.2 PCR for Gene Rearrangements
4.4.3.3 NGS and Multiplexing
5.1 Approval Scenario
5.1.1 Approved Minimal Residual Disease Tests by Major Players
5.1.2 Launched Minimal Residual Disease Tests by Major Players
5.2 Financing Scenario
5.2.1 Key Players Stratification (as Per Raised Financing Value)
5.2.2 Key Players Financing Analysis (FY2017-2019)
5.3 Regulatory Framework
5.3.1 Legal Requirements and Framework in U.S.
5.3.2 Legal Requirements and Framework in Europe
5.3.3 Legal Requirements and Framework in Asia-Pacific
5.3.3.1 Japan
5.3.3.2 China
5.3.3.3 India
5.4 Reimbursement Scenario
5.4.1 North America
5.4.1.1 OPD vs IPD
5.4.2 European Union
5.4.2.1 OPD vs IPD
5.4.3 Asia-Pacific
5.5 Supply Chain Analysis
5.5.1 For Laboratory Developed Tests (LDTs)
5.5.2 For In-Vitro Diagnostics (IVDs)
5.6 Minimal Residual Disease Testing Government Initiatives
5.6.1 Technology Consideration for Minimal Residual Disease
5.6.1.1 Considerations for Cellular Technology Platforms
5.6.1.2 Considerations for Molecular Technology Platforms
5.6.1.3 Considerations for Sample
5.7 Impact of COVID-19 on Minimal Residual Disease Testing Market
5.7.1 Considerations With Inpatients
5.7.2 Considerations With Outpatients
5.8 Price Sensitivity Analysis (Elasticity)
5.8.1 Physicians’ Perception
5.8.1.1 Turnaround Time (TAT)
5.8.1.2 Test Sensitivity
5.8.2 Investors’ Perception
5.8.2.1 Turnaround Time (TAT)
5.8.2.2 Test Sensitivity
5.8.3 Payors’ Perception
5.8.3.1 Turnaround Time (TAT)
5.8.3.2 Test Sensitivity
6.1 Overview
6.2 Synergistic Activities
6.3 Approvals
6.4 Product Launches and Updates
6.5 Other Developments
6.6 Market Share Analysis, 2018-2019
6.7 Growth Share Analysis
6.7.1 Growth Share Analysis (by Company)
6.7.2 Growth Share Analysis (by Technology)
6.7.3 Growth Share Analysis (by Application)
6.7.4 Growth Share Analysis (by End User)
7.1 Overview
7.2 Flow Cytometry
7.3 Polymerase Chain Reaction (PCR)
7.4 Next-Generation Sequencing (NGS)
7.5 Other Technologies
8.1 Overview
8.2 Hematological Malignancies
8.2.1 Non-Hodgkin’s Lymphoma (NHL)
8.2.1.1 Non-Hodgkin’s Lymphoma (NHL) (by Type)
8.2.1.2 Non-Hodgkin’s Lymphoma (NHL) (by Age)
8.2.2 Multiple Myeloma (MM)
8.2.2.1 Multiple Myeloma (MM) (by Age)
8.2.3 Acute Lymphoblastic Leukemia (ALL)
8.2.3.1 Acute Lymphoblastic Leukemia (ALL) (by Age)
8.2.4 Chronic Lymphocytic Leukemia (CLL)
8.2.4.1 Chronic Lymphocytic Leukemia (CLL) (by Age)
8.2.5 Acute Myeloid Leukemia (AML)
8.2.5.1 Acute Myeloid Leukemia (AML) (by Age)
8.2.6 Chronic Myeloid Leukemia (CML)
8.2.6.1 Chronic Myeloid Leukemia (CML) (by Age)
8.2.7 Hodgkin’s Lymphoma (HL)
8.2.7.1 Hodgkin’s Lymphoma (HL) (by Age)
8.2.8 Other Leukemia
9.1 Overview
9.2 Specialty Clinics and Hospitals
9.3 Diagnostic Laboratories
9.4 Research Institutions
9.5 Other End Users
10.1 Overview
10.2 North America
10.2.1 U.S.
10.2.1.1 U.S. Minimal Residual Disease Testing Market (by Application)
10.2.2 Canada
10.2.2.1 Canada Minimal Residual Disease Testing Market (by Application)
10.3 Europe
10.3.1 Germany
10.3.1.1 Germany Minimal Residual Disease Testing Market (by Application)
10.3.2 Italy
10.3.2.1 Italy Minimal Residual Disease Testing Market (by Application)
10.3.3 France
10.3.3.1 France Minimal Residual Disease Testing Market (by Application)
10.3.4 U.K.
10.3.4.1 U.K. Minimal Residual Disease Testing Market (by Application)
10.3.5 Spain
10.3.5.1 Spain Minimal Residual Disease Testing Market (by Application)
10.3.6 Rest-of-Europe
10.3.6.1 Rest-of-Europe Minimal Residual Disease Testing Market (by Application)
10.4 Asia-Pacific
10.4.1 China
10.4.1.1 China Minimal Residual Disease Testing Market (by Application)
10.4.2 India
10.4.2.1 India Minimal Residual Disease Testing Market (by Application)
10.4.3 Japan
10.4.3.1 Japan Minimal Residual Disease Testing Market (by Application)
10.4.4 South Korea
10.4.4.1 South Korea MRD Testing Market (by Application)
10.4.5 Australia
10.4.5.1 Australia Minimal Residual Disease Testing Market (by Application)
10.4.6 Singapore
10.4.6.1 Singapore Minimal Residual Disease Testing Market (by Application)
10.4.7 Rest-of-APAC (RoAPAC)
10.4.7.1 Rest-of-APAC Minimal Residual Disease Testing Market (by Application)
10.5 Latin America and Middle East
10.5.1 Brazil
10.5.1.1 Brazil Minimal Residual Disease Testing Market (by Application)
10.5.2 Mexico
10.5.2.1 Mexico Minimal Residual Disease Testing Market (by Application)
10.5.3 Saudi Arabia
10.5.3.1 Saudi Arabia Minimal Residual Disease Testing Market (by Application)
10.5.4 Rest-of-Latin America and Middle East
10.5.4.1 Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application)
10.6 Rest-of-the-World (RoW)
10.6.1.1 Rest-of-the-World Minimal Residual Disease Testing Market (by Application)
11.1 ICON plc
11.1.1 Company Overview
11.1.2 Role of ICON plc in Global Minimal Residual Disease Testing Market
11.1.3 Financials
11.1.4 SWOT Analysis
11.2 ArcherDX, Inc. (Part of Invitae Corporation)
11.2.1 Company Overview
11.2.2 Role of ArcherDX, Inc. in Global Minimal Residual Disease Testing Market
11.2.3 SWOT Analysis
11.3 ARUP Laboratories
11.3.1 Company Overview
11.3.2 Role of ARUP Laboratories in Global Minimal Residual Disease Testing Market
11.3.3 SWOT Analysis
11.4 ASURAGEN INC.
11.4.1 Company Overview
11.4.2 Role of ASURAGEN Inc. in Global Minimal Residual Disease Testing Market
11.4.3 SWOT Analysis
11.5 Cergentis B.V.
11.5.1 Company Overview
11.5.2 Role of Cergentis B.V. in Global Minimal Residual Disease Testing Market
11.5.3 SWOT Analysis
11.6 Bio-Rad Laboratories, Inc.
11.6.1 Company Overview
11.6.2 Role of Bio-Rad Laboratories, Inc. in Global Minimal Residual Disease Testing Market
11.6.3 Financials
11.6.4 Key Insights About Financial Health of the Company
11.6.5 SWOT Analysis
11.7 Mission Bio, Inc.
11.7.1 Company Overview
11.7.2 Role of Mission Bio, Inc. in Global Minimal Residual Disease Testing Market
11.7.3 SWOT Analysis
11.8 Guardant Health
11.8.1 Company Overview
11.8.2 Role of Guardant Health in Global Minimal Residual Disease Testing Market
11.8.3 Financials
11.8.4 SWOT Analysis
11.9 Invivoscribe, Inc.
11.9.1 Company Overview
11.9.2 Role of Invivoscribe, Inc. in Global Minimal Residual Disease Testing Market
11.9.3 SWOT Analysis
11.10 Laboratory Corporation of America Holdings
11.10.1 Company Overview
11.10.2 Role of Laboratory Corporation of America Holdings in Global Minimal Residual Disease Testing Market
11.10.3 Financials
11.10.4 SWOT Analysis
11.11 Inivata Ltd.
11.11.1 Company Overview
11.11.2 Role of Inivata Ltd. in Global Minimal Residual Disease Testing Market
11.11.3 SWOT Analysis
11.12 Natera, Inc.
11.12.1 Company Overview
11.12.2 Role of Natera, Inc. in Global Minimal Residual Testing Market
11.12.3 Financials
11.12.4 Key Insights About Financial Health of the Company
11.12.5 SWOT Analysis
11.13 NeoGenomics Laboratories, Inc.
11.13.1 Company Overview
11.13.2 Role of NeoGenomics Laboratories, Inc. in Global Minimal Residual Testing Market
11.13.3 Financials
11.13.4 Key Insights About Financial Health of the Company
11.13.5 SWOT Analysis
11.14 Opko Health, Inc.
11.14.1 Company Overview
11.14.2 Role of Opko Health, Inc. in Global Minimal Residual Disease Testing Market
11.14.3 Financials
11.14.4 Key Insights About Financial Health of the Company
11.14.5 SWOT Analysis
11.15 Quest Diagnostics Incorporated
11.15.1 Company Overview
11.15.2 Role of Quest Diagnostics Incorporated in Global Minimal Residual Disease Testing Market
11.15.3 Financials
11.15.4 SWOT Analysis
11.16 Sysmex Corporation
11.16.1 Company Overview
11.16.2 Role of Sysmex Corporation in Global Minimal Residual Disease Testing Market
11.16.3 Financials
11.16.4 Key Insights About Financial Health of the Company
11.16.5 SWOT Analysis
11.17 Adaptive Biotechnologies Corporation
11.17.1 Company Overview
11.17.2 Role of Adaptive Biotechnologies Corporation in Global Minimal Residual Disease Testing Market
11.17.3 Financials
11.17.4 Key Insights About Financial Health of the Company
11.17.5 SWOT Analysis
Table 4.1: Likert Scale
Table 4.2: Impact Analysis of Market Drivers
Table 4.3: Impact Analysis of Market Restraints
Table 5.1: List of Approved MRD Tests by Major Players
Table 5.2: List of Launched MRD Tests by Major Players
Table 5.3: Key Notable Developments
Table 5.4: Comparison of FDA and EMA Draft Guidance
Table 5.5: Registration Criteria for IVD Medical Devices as per CFDA
Table 5.6: Key Coverage Providers for Hematologic Malignancies Testing
Table 7.1: Key Products Offered Based on Flow Cytometry
Table 7.2: Key Products Offered Based on PCR
Table 7.3: Key Products Offered Based on NGS
Figure 1: Incidence of Age-Standardized Incident Rates for Cancer Globally, 2020
Figure 2: Relative Percent of New Lymphomas Expected in U.S. in 2020
Figure 3: Prevalence of Different Hematological Malignancies Across U.S. (2013-2017)
Figure 4: Impact Analysis on the Global Minimal Residual Disease Testing Market
Figure 5: Global MRD Testing Market (by Application), $Million, 2019 vs. 2025
Figure 6: Global MRD Testing Market (by Hematological Malignancy), $Million, 2019 vs. 2025
Figure 7: Global Minimal Residual Disease Testing Market (by Technology), $Million, 2019 vs. 2025
Figure 8: Global Minimal Residual Disease Testing Market (by End User), $Million, 2019 vs. 2025
Figure 9: Global Minimal Residual Disease Testing Market Snapshot
Figure 1.1: Global MRD Testing Market Segments
Figure 2.1: Bottom-Up Approach (Segment-Wise Analysis)
Figure 2.2: Top-Down Approach (Segment-Wise Analysis)
Figure 3.1: Global MRD Testing Market, $Million, 2018-2025
Figure 3.2: Global MRD Testing Market Potential, $Million, 2019-2025
Figure 4.1: Global Incidence and Mortality Rate for Individual Hematological Conditions (2016)
Figure 4.2: Estimated New Cases of Hematological Cancer, 2020
Figure 5.3: Laboratory Methods for MRD Detection
Figure 5.4: Classification on In-Vitro Diagnostics in India
Figure 5.5: Methods to Achieve Coverage
Figure 5.6: Supply Chain Analysis of Laboratory Developed Tests
Figure 5.7: Supply Chain Analysis of In-Vitro Diagnostics
Figure 6.1: Share of Key Developments and Strategies, January 2018-December 2020
Figure 6.2: Synergistic Activities Share (by Company), January 2018-December 2020
Figure 6.3: Market Share Analysis for Global MRD Testing Market, 2018 and 2019
Figure 6.4: Growth Share Analysis for Global MRD Testing Market (by Company), 2019
Figure 6.5: Growth Share Analysis for Global MRD Testing Market (by Technology), 2019-2025
Figure 6.6: Growth Share Analysis for Global MRD Testing Market (by Application), 2019-2025
Figure 6.7: Growth Share Analysis for Global MRD Testing Market (by End User), 2019-2025
Figure 7.1: Global Minimal Residual Disease Testing Market (by Technology), $Million, 2019-2025
Figure 7.2: Global Minimal Residual Disease Testing Market (by Flow Cytometry), $Million, 2019-2025
Figure 7.3: Global Minimal Residual Disease Testing Market (PCR), $Million, 2019-2025
Figure 7.4: Global Minimal Residual Disease Testing Market (NGS), $Million, 2019-2025
Figure 7.5: Global Minimal Residual Disease Testing Market (Other Technologies), $Million, 2019-2025
Figure 8.1: Global MRD Testing Market (by Application)
Figure 8.2: Global MRD Testing Market (by Application), 2019-2025
Figure 8.3: Global MRD Testing Market (by Hematological Malignancies), 2019 vs. 2025
Figure 8.4: Global Minimal Residual Disease Testing Market (Non-Hodgkin’s Lymphoma), $Million, 2019-2025
Figure 8.5: Global Minimal Residual Disease Testing Market (by Non-Hodgkin’s Lymphoma Type), $Million, 2019-2025
Figure 8.6: Global NHL MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.7: Global Minimal Residual Disease Testing Market (Multiple Myeloma), $Million, 2019-2025
Figure 8.8: Global MM-MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.9: Global Minimal Residual Disease Testing Market (Acute Lymphoblastic Leukemia), $Million, 2019-2025
Figure 8.10: Global ALL-MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.11: Global Minimal Residual Disease Testing Market (Chronic Lymphocytic Leukemia), $Million, 2019-2025
Figure 8.12: Global CLL-MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.13: Global Minimal Residual Disease Testing Market (Acute Myeloid Leukemia), $Million, 2019-2025
Figure 8.14: Global AML-MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.15: Global Minimal Residual Disease Testing Market (Chronic Myeloid Leukemia), $Million, 2019-2025
Figure 8.16: Global CML-MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.17: Global Minimal Residual Disease Testing Market (Hodgkin’s Lymphoma), $Million, 2019-2025
Figure 8.18: Global HL-MRD Testing Market (by Age), $Million, 2019-2025
Figure 8.19: Global Minimal Residual Disease Testing Market (Other Leukemia), $Million, 2019-2025
Figure 9.1: Global Minimal Residual Disease Testing Market (by End User), $Million, 2019-2025
Figure 9.2: Specialty Clinics and Hospitals Market, $Million, 2019-2025
Figure 9.3: Diagnostic Laboratories Market, $Million, 2019-2025
Figure 9.4: Research Institutions Market, $Million, 2019-2025
Figure 9.5: Global Minimal Residual Disease Testing Market (Other End Users), $Million, 2019-2025
Figure 10.1: Global Minimal Residual Disease Testing Market (by Region), $Million, 2019 and 2025
Figure 10.2: North America: Market Dynamics
Figure 10.3: North America Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.4: North America Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025
Figure 10.5: U.S. Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.6: U.S. Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.7: Growth-Share Analysis for U.S. Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.8: Canada Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.9: Canada Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.10: Growth-Share Analysis for Canada Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.11: Europe: Market Dynamics
Figure 10.12: Europe Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.13: Europe Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025
Figure 10.14: Germany Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.15: Germany Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.16: Growth-Share Analysis for Germany Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.17: Italy Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.18: Italy Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.19: Growth-Share Analysis for Italy Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.20: France Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.21: France Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.22: Growth-Share Analysis for France Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.23: U.K. Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.24: U.K. Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.25: Growth-Share Analysis for U.K. Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.26: Spain Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.27: Spain Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.28: Growth-Share Analysis for Spain Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.29: Rest-of-Europe Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.30: Rest-of-Europe Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.31: Growth-Share Analysis for Rest-of-Europe Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.32: Asia-Pacific: Market Dynamics
Figure 10.33: Asia-Pacific Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.34: Asia-Pacific Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025
Figure 10.35: China Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.36: China Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.37: Growth-Share Analysis for China Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.38: India Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.39: India Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.40: Growth-Share Analysis for India Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.41: Japan Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.42: Japan Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.43: Growth-Share Analysis for Japan Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.44: South Korea Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.45: South Korea Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.46: Growth Share Analysis for South Korea MRD Testing Market (by Application), 2019-2025
Figure 10.47: Australia Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.48: Australia Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.49: Growth-Share Analysis for Australia Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.50: Number of Death in Australia by Leukemia (2012-2017)
Figure 10.51: Singapore Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.52: Singapore Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.53: Growth-Share Analysis for Singapore Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.54: Rest-of-APAC Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.55: Rest-of-APAC Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.56: Growth-Share Analysis for Rest-of-APAC Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.57: Latin America: Market Dynamics
Figure 10.58: Latin America and Middle East Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.59: Latin America and Middle East Minimal Residual Disease Testing Market (by Country), $Million, 2019 vs. 2025
Figure 10.60: Brazil Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.61: Brazil Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.62: Growth-Share Analysis for Brazil Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.63: Mexico Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.64: Mexico Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.65: Growth-Share Analysis for Mexico Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.66: Saudi Arabia Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.67: Saudi Arabia Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.68: Growth-Share Analysis for Saudi Arabia Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.69: Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.70: Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.71: Growth-Share Analysis for Rest-of-Latin America and Middle East Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 10.72: Rest-of-the-World Minimal Residual Disease Testing Market, $Million, 2019-2025
Figure 10.73: Rest-of-the-World Minimal Residual Disease Testing Market (by Application), $Million, 2019-2025
Figure 10.74: Growth-Share Analysis for Rest-of-the-World Minimal Residual Disease Testing Market (by Application), 2019-2025
Figure 11.1: ICON plc: Overall Product Portfolio
Figure 11.2: ICON plc: Overall Financials, 2017-2019
Figure 11.3: ICON plc: Revenue (by Region), 2017-2019
Figure 11.5: ArcherDX, Inc.: Portfolio
Figure 11.6: ArcherDX, Inc.: SWOT Analysis
Figure 11.7: ARUP Laboratories: Product Portfolio
Figure 11.8: ARUP Laboratories: SWOT Analysis
Figure 11.9: ASURAGEN INC.: Product Portfolio
Figure 11.10: ASURAGEN INC.: SWOT Analysis
Figure 11.11: Cergentis B.V.: Product Portfolio
Figure 11.12: Cergentis B.V.: SWOT Analysis
Figure 11.13: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 11.14: Bio-Rad Laboratories, Inc.: Overall Financials, 2017-2019
Figure 11.15: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 11.16: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2017-2019
Figure 11.17: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 11.18: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 11.19: Mission Bio, Inc.: Product Portfolio
Figure 11.20: Mission Bio, Inc.: SWOT Analysis
Figure 11.21: Guardant Health: Portfolio
Figure 11.22: Guardant Health: Overall Financials, 2017-2019
Figure 11.23: Guardant Health: Revenue (by Segment), 2017-2019
Figure 11.24: Guardant Health: Revenue (by Region), 2017-2019
Figure 11.25: Guardant Health: SWOT Analysis
Figure 11.26: Invivoscribe, Inc.: Product Portfolio
Figure 11.27: Invivoscribe, Inc.: SWOT Analysis
Figure 11.28: Laboratory Corporation of America Holdings: Product Portfolio
Figure 11.29: Laboratory Corporation of America Holdings: Overall Financials, 2017-2019
Figure 11.30: Laboratory Corporation of America Holdings: Revenue (by Segment), 2017-2019
Figure 11.31: Laboratory Corporation of America Holdings: Revenue (by Region), 2019
Figure 11.32: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 11.33: Inivata Ltd.: Product Portfolio
Figure 11.34: Inivata Ltd.: SWOT Analysis
Figure 11.35: Natera, Inc.: Portfolio
Figure 11.36: Natera, Inc.: Overall Financials, 2017-2019
Figure 11.37: Natera, Inc.: Revenue (by Segment), 2017-2019
Figure 11.38: Natera, Inc.: R&D Expenditure, 2017-2019
Figure 11.39: Natera, Inc.: SWOT Analysis
Figure 11.40: NeoGenomics Laboratories, Inc.: Portfolio
Figure 11.41: NeoGenomics Laboratories, Inc.: Overall Financials, 2017-2019
Figure 11.42: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2017-2019
Figure 11.43: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2017-2019
Figure 11.44: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 11.45: Opko Health: Portfolio
Figure 11.46: Opko Health, Inc.: Overall Financials, 2017-2019
Figure 11.47: Opko Health, Inc.: Revenue (by Segment), 2017-2019
Figure 11.48: Opko Health, Inc.: Revenue (by Region), 2017-2019
Figure 11.49: Opko Health, Inc.: R&D Expenditure, 2017-2019
Figure 11.50: Opko Health, Inc.: SWOT Analysis
Figure 11.51: Quest Diagnostics Incorporated: Product Portfolio
Figure 11.52: Quest Diagnostics Incorporated: Overall Financials, 2017-2019
Figure 11.53: Quest Diagnostics Incorporated: SWOT Analysis
Figure 11.54: Sysmex Corporation: Product Portfolio
Figure 11.55: Sysmex Corporation: Overall Financials, 2017-2019
Figure 11.56: Sysmex Corporation: Revenue (by Business Segment), 2018-2019
Figure 11.57: Sysmex Corporation R&D Expenditure, 2017-2019
Figure 11.58: Sysmex Corporation: SWOT Analysis
Figure 11.59: Adaptive Biotechnologies Corporation: Product Portfolio
Figure 11.60: Adaptive Biotechnologies Corporation: Overall Financials, 2017-2019
Figure 11.61: Adaptive Biotechnologies Corporation: Revenue (by Business Segment), 2017-2019
Figure 11.62: Adaptive Biotechnologies Corporation R&D Expenditure, 2017-2019
Figure 11.63: Adaptive Biotechnologies Corporation: SWOT Analysis
|
Market Report Coverage - MRD Testing |
|||
|
Base Year |
2019 |
Market Size in 2019 |
$694.0 Million |
|
Forecast Period |
2020-2025 |
Value Projection and Estimation by 2025 |
$1.61 Billion |
|
CAGR During Forecast Period |
15.64% |
Number of Tables |
12 |
|
Number of Pages |
262 |
Number of Figures |
193 |
|
Research Hours |
|
|
|
|
Market Segmentation |
• Technology – Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), and Other Technologies • Application – Hematological Malignancies (Non-Hodgkin’s Lymphoma, Multiple Myeloma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia Leukemia, Hodgkin’s Lymphoma, and Other Leukemia) and Solid Tumor • End User – Specialty Clinics and Hospitals, Diagnostic Laboratories, Research Institutions, and Other End Users |
||
|
Regional Segmentation |
• North America – U.S., and Canada • Europe – Germany, Italy, France, U.K., Spain, and Rest-of-Europe • Asia-Pacific – China, India, Japan, South Korea, Australia, Singapore, and Rest-of-Asia-Pacific • Latin America & Middle East – Brazil, Mexico, Saudi Arabia, and Rest-of-Latin America and Middle East • Rest-of-the-World |
||
|
Growth Drivers |
• Rising Incidence of Hematologic Malignancies • Increasing Consumer Awareness for Tailored Therapy • Increase in Research Funding from National Cancer Institute • Increasing Disposable Income in Emerging Economies |
||
|
Market Challenges |
• False Negatives and Positives • Uncertain Reimbursement and Regulatory Policies • Lack of Trained Professionals • Lack of Established Treatment Protocols for High-Value Tests in Emerging Economies |
||
|
Market Opportunities |
• Potential Long-Term Cost Savings • Increasing Market Access in Emerging Economies • Technological Evolution of Testing |
||
|
Key Companies Profiled |
ICON plc, ArcherDX, Inc. (Part of Invitae Corporation), Arup Laboratories, ASURAGEN INC., Cergentis B.V., Bio-Rad Laboratories, Inc., Mission Bio, Inc., Guardant Health, Invivoscribe, Inc., Laboratory Corporation of America Holdings, Inivata Ltd., Natera, Inc., NeoGenomics Laboratories, Inc., Opko Health, Inc., Quest Diagnostics Incorporated, Sysmex Corporation, Adaptive Biotechnologies Corporation |
||
• What are the major market drivers, challenges, and opportunities and their respective impacts in the global MRD testing market?
• What is the potential impact of biotechnological advancement in the diagnostic industry among end users, such as physicians, researchers, pathologists, and laboratory technicians?
• What is the current market demand along with future expected demand for the global MRD testing market?
• Has MRD testing penetrated major countries facing an immense burden from hematological malignancies?
• What are the key regulatory hurdles for industry players looking to enter this highly dynamic market?
• What are the key development strategies that are implemented by the major players in order to sustain in the competitive market?
• How is each segment of the market expected to grow during the forecast period from 2020 to 2025 based on each segment?
o Technology (flow cytometry, PCR, NGS, and other technologies)
o Application (hematological malignancy and solid tumor)
o End user (specialty clinics and hospitals, diagnostic laboratories, research institutions, and other end users)
o Region (North America, Europe, Asia-Pacific, Latin America & Middle East, and Rest-of-the-World)
• Which are the leading players with significant offerings to the global MRD testing market? What is the expected market dominance for each of these leading players?
• Which emerging companies are anticipated to be highly disruptive in the future, and what are their key strategies for sustainable growth in the global MRD testing market?
Our healthcare experts have found the MRD Testing industry to be one of the most rapidly evolving and dynamic markets. The global market for MRD testing is predicted to grow at a CAGR of 15.64% over the forecast period, 2020-2025. The market is driven by certain factors, such as the rising incidence of hematologic malignancies, the increasing consumer awareness for tailored therapy, the increasing research funding from the National Cancer Institute, and the increasing disposable income in emerging economies.
The market is favored by the developments in the field of MRD testing solutions for hematologic malignancies and solid tumors. Currently, the MRD testing industry is witnessing an upsurge due to the rising incidence of hematologic malignancies, resulting in the high demand for sensitive testing solutions. Additionally, the high adoption of MRD tests among patients and the growing awareness among physicians regarding MRD testing are some of the critical factors expected to bolster the market growth.
Furthermore, diagnostic companies are focusing on the development of NGS-based MRD tests for lymphoid malignancies, having higher sensitivity and low turnaround time to benefit the patients suffering from hematologic malignancies.
Within the research report, the market is segmented on the basis of technology, application, end user, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the number of cases associated with hematological malignancies has created a buzz among the diagnostic companies to further invest in the development of reliable, sensitive, and rapid MRD testing solutions to aid patients to get into remission. Due to the presence of a diverse product portfolio and intense market penetration, Invivoscribe, Inc. has been a pioneer in this field and has been a significant competitor in this market.
On the basis of region, North America holds the largest share of the MRD testing market due to high infusion of funding from government organizations for conducting research on hematological malignancies, rising incidence of hematological malignancies, and high adoption of technologically advanced MRD tests, among others. Apart from this, Asia-Pacific is anticipated to grow at the fastest CAGR during the forecast period, 2020-2025.
The MRD testing market was estimated at $694.0 million in 2019 and is expected to grow at a CAGR of 15.64% during the forecast period 2020-2025.
Factors that are driving the growth of the market include rising incidence of hematologic malignancies, increasing consumer awareness for tailored therapy, increase in research funding from national cancer institute, and increasing disposable income in emerging economies.
Technologies covered under MRD testing market include flow cytometry, polymerase chain reaction (PCR), next-generation sequencing (NGS), and other technologies.
Application where MRD testing can be used include hematological malignancies (non-Hodgkin’s lymphoma, multiple myeloma, acute lymphoblastic leukemia, acute myeloid leukemia, chronic myeloid Leukemia, Hodgkin’s lymphoma, and other leukemia) and solid tumor.
Key companies operating in the market include ICON plc, ArcherDX, Inc. (Part of Invitae Corporation), Arup Laboratories, ASURAGEN INC., Cergentis B.V., Bio-Rad Laboratories, Inc., Mission Bio, Inc., Guardant Health, Invivoscribe, Inc., and Laboratory Corporation of America Holdings.
In 2019, the market size of the global tumor genomics market was valued at $8,131.0 million,...
The hematologic malignancies testing industry analysis by BIS Research projects the market to...
Focus on Technology, Application, End User, Region and Competitive Landscape - Analysis and Forecast, 2020-2025
